The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1235
May 22, 2006
View Complete Issue         Table of Contents 2019 
Transdermal Selegiline (Emsam)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Transdermal Selegiline (Emsam)
May 22, 2006 (Issue: 1235)
The FDA recently approved the monoamine oxidase inhibitor (MAOI) selegiline in a transdermal (patch) formulation (Emsam - Bristol-Myers Squibb/Somerset) for treatment of major depressive disorder. Selegiline is also available in an oral formulation...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Transdermal Selegiline (Emsam)
Article code: 1235a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.